Miranda Jayne Toledano - 31 Jul 2024 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Issuer symbol: ENTX
Transactions as of: 31 Jul 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Aug 2024, 16:30:44 UTC
Previous filing: 10 Jul 2024
Next filing: 07 Jul 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	$0	+124,121	+112%	$0.000000	234,873	31 Jul 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (Right to Buy)	Award	$0	+500,000		$0.000000	500,000	31 Jul 2024	Ordinary Shares, par value NIS 0.0000769 per share	500,000	$1.99	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
F2	This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Content

Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.